KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Bio-Rad Laboratories (BIO) Debt to Equity (2016 - 2026)

Bio-Rad Laboratories has reported Debt to Equity over the past 18 years, most recently at $0.12 for Q1 2026.

  • Quarterly Debt to Equity fell 34.81% to $0.12 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $0.12 through Mar 2026, down 34.81% year-over-year, with the annual reading at $0.16 for FY2025, 11.77% down from the prior year.
  • Debt to Equity was $0.12 for Q1 2026 at Bio-Rad Laboratories, down from $0.16 in the prior quarter.
  • Over five years, Debt to Equity peaked at $0.18 in Q4 2024 and troughed at $0.12 in Q1 2026.
  • The 5-year median for Debt to Equity is $0.14 (2023), against an average of $0.15.
  • Year-over-year, Debt to Equity surged 20241.86% in 2022 and then crashed 34.81% in 2026.
  • A 5-year view of Debt to Equity shows it stood at $0.12 in 2022, then increased by 10.13% to $0.14 in 2023, then soared by 33.21% to $0.18 in 2024, then dropped by 11.77% to $0.16 in 2025, then fell by 27.31% to $0.12 in 2026.
  • Per Business Quant, the three most recent readings for BIO's Debt to Equity are $0.12 (Q1 2026), $0.16 (Q4 2025), and $0.18 (Q3 2025).